

# Repeating exceptionals

## Identifying outliers amongst the noise of non-GAAP earnings

Free to View  
ESG - Global

- ◆ Our data science and forensic accounting methodology prioritises which companies' adjustments appear "large"
- ◆ Considering these accounting choices can provide valuable insight to investors
- ◆ We re-run our 2021 analysis on the FTSE100, FTSE250, STOXX600 and JSE140

### Why we think investors should look at adjustments

The use of exceptional items or "adjustments" to earnings by companies is widespread. Companies have total discretion on how to define these non-GAAP "adjusted" metrics, which are almost more positive than the IFRS numbers. But, considering what a company has invited one to ignore can be valuable. We think adjustments may alert investors to companies that:

- ◆ may be under financial pressure, e.g. potentially under recognising costs;
- ◆ are trying to set the scene for a future narrative;
- ◆ have over-valued assets (that perhaps should have been written down previously) in order to provide a lower capital employed value; and
- ◆ may be taking provisions to provide a buffer to reverse in future years.

### Our unique combined data science and forensic accounting approach

In 2021 we developed an approach to prioritise the companies where a closer look at exceptional items may be required. Our "**Non-linear Combination Score**" ("**NLCS**") method provides a relative scoring rating of the size of the adjustments made by each company with reference to the size of those adjustments compared to a company's individual captions (e.g. Revenue or EBITDA).

### We rerun our 2021 analysis on the FTSE100, FTSE250, STOXX600 and JSE140

Although individual companies moved, at an index level there was, unfortunately, still a substantive level of adjustments, again the majority being additive. We found 575, (61%) of companies reported net additive adjustments and 46 of companies in all four indexes had adjusted items that were in excess of 50% of average adjusted EBITDA.

### Our forensic accountant's approach to considering individual adjustments

We revisit our forensic accounting approach to considering exceptional items on a granular level having used our method to prioritise which to look at.

*This is a Free to View version of a report with the same title published on 13-May-22. Please contact your HSBC representative or email [AskResearch@hsbc.com](mailto:AskResearch@hsbc.com) for more information.*

---

**Dylan Whitfield, FCA**  
Head of Forensic Accounting  
HSBC Bank plc

**Mark McDonald**  
Head of Data Science and Analytics  
HSBC Bank plc

**Rahul Chopra\***  
Analyst  
HSBC Securities and Capital Markets (India) Private Limited

---

\* Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/ qualified pursuant to FINRA regulations

---

### Disclosures & Disclaimer

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

Issuer of report: HSBC Bank plc

View HSBC Global Research at:  
<https://www.research.hsbc.com>

# Outliers from the normal “unusual” items

- ◆ Companies have complete latitude in defining “adjusted” metrics. They are widely used and almost always present a “rosier” picture than the straightforward GAAP numbers.
- ◆ Considering these elective accounting choices can provide valuable insight to investors.
- ◆ Our data science and forensic prioritisation approach prioritises which companies may have levels of adjustment that warrant a closer look.

## Why we look at the use of exceptional items

### Subtle signs can be more useful than looking for a “red flag”

When attempting to identify issues and risk from an accounting perspective, there is no single “red flag” or test to determine when there might be an issue. Often when a problem gets to the point that it becomes obvious from an outsider’s perspective it is often too late to do anything about it. We therefore prefer to look for subtle signs of risk or concern. We often focus our attention on areas that are subject to subjectivity, estimation or accounting choice.

Adjustments and exceptional items are one such area (as management can define these for themselves) and considering what the management of a company suggests one should ignore is often worth the effort.

In our view, understanding the adjustments and exclusions being made by companies can alert investors to:

- ◆ **companies that may be under financial pressure:** potential under recognition or deferral/moving of costs out of “underlying” (e.g. a capitalisation of costs then writing off/amortising or perhaps over-optimistic assumptions for write-downs) and into exceptional items could provide a more flattering picture of “underlying” / or “recurring” earnings;
- ◆ companies looking to manage the narrative (e.g. rebasing numbers to deliver “growth”) by, for example:
  - over-recognising costs (either in exceptional or underlying) in the current year in order to provide a **lower cost base/higher margins/better growth rates in subsequent years;**
  - writing down assets in the current year (that perhaps should have been written down previously) for example to provide a **lower capital employed in subsequent years;** or
  - taking provisions to provide a buffer to reverse in subsequent years;
- ◆ **a selective accounting posture** (which could extend beyond the exceptional items); and
- ◆ issues in relation to the financial control and governance of a company.

**However, we stress that while large exceptional items MAY be indicators of the above** there are, in many instances, good reasons for large adjustments (and these are often helpful to investors). Therefore, for the avoidance of doubt, we advocate a granular analysis before drawing any inferences or conclusions.

---

**Over reliance on “adjustments” can be a subtle sign**

---

**By any measure, distributable reserves do not equal “adjusted” EBITDA**

**Assuming “adjusted” results drop through to distributions may be a risky assumption**

We also advise caution when considering adjusted metrics because distributions (i.e. dividends and returns of capital) will ultimately come out of (some form of) profits after all expenses. Therefore, despite all the plausible rationale provided by company management that “adjusted” is a better reflection of the performance of the business, unadjusted profits are what may ultimately be due to shareholders via distributions.

As we set out in [Accounting for dividends \(15 Feb 2022\)](#), although there are different rules for what profits are available for distribution to those disclosed as consolidated profits, we think that it is fair to say that in most (although not all) scenarios profits recognised each year into retained earnings are likely to be closer to what is distributable than any non-GAAP measures such as “adjusted” EBITDA, and adjusted EPS although, again it is not that simple and there can be significant divergences.

Consequently, we think that non-GAAP measures, although sometimes helpful, should be treated with care and scepticism, and the **unadjusted** earnings should, in most cases, be given at least equal weight when considering the financial performance of a company.

**Updating our work – although there are still impacts of disruption, there are still the “normal” levels of exceptional items to consider**

**We re-run our analysis for the latest numbers**

Last autumn we set out our combined data science and forensic accounting approach to consider the level of adjustments (or “exceptional items”) that companies are making to their earnings in order to prioritise which companies within an index may warrant a closer look.

In that report, we set out the result of that analysis on companies the FTSE100, FTSE250, STOXX600 and JSE140 indices, and highlighted companies that appeared to be making greater, more regular use of exceptional items.

**Getting back to “normal”, but is “normal” the right answer?**

Although our previous (and most likely our more recent) analysis likely include some of the effects of COVID-19 related adjustments, the level of use of exceptional items (usually additive) by companies is, unfortunately, widespread even in a “normal” year.

We have demonstrated in previous reports that such items are often material and in one direction (i.e. additive to earnings). We think that the previous chairman of The International Accounting Standards Board (the “IASB”) summed up the issue perfectly:

**“ For some reason, companies often find it much easier to find unusual expenses than unusual items of income. It is the main reason why 80%–90% of non-GAAP measures present a rosier picture than numbers reported using IFRS.”**

**Hans Hoogervorst, (previous) IASB Chairman**

**Therefore, it comes as no surprise** to find again that a significant number of companies are using large adjustments to adjust up their earnings.

**Full details of our analysis can be found in the main research report available to clients of HSBC Global Research, including a discussion on why despite performing a granular analysis is key, it must be prioritised by considering the relative size of exceptional items to various factors – and why we use data science to perform these tasks. Please contact your HSBC representative or email [AskResearch@hsbc.com](mailto:AskResearch@hsbc.com) for more information.**

---

**Getting back to “normal” i.e. still significant adjustments**

---

After prioritisation comes the granular work

## A forensic approach for considering exceptional items

### Having prioritised the companies for further analysis, what might that analysis be?

As with much accounting analysis, there is no “standard” approach for identifying issues with exceptional items. We have set out below a list of questions that investors may find helpful. These questions are not intended to be exhaustive, nor are they specific to a particular company. Rather, we suggest these as a starting point that can be used in conjunction with a healthy level of scepticism to consider these items, which should also ideally be triangulated to other information where possible.

### Questions investors should consider

1. **What narrative is the company trying to present?**
2. **What metrics are being presented (or are important to stakeholders) and how do the exceptional items affect those metrics?**
3. **Is there a possibility that directors’ remuneration and incentives are driving accounting estimates?**
4. **What opportunities might the company have or use in order to move costs around?**
5. **Where a company has recognised exceptional items or additional costs due to disruptions:**
  - a. is there a clear linkage between “cause and effect”;
  - b. has the company been “*even-handed in identifying any gains as well as losses*”;
  - c. are there any indications that the costs may not be one-off; and
  - d. do write downs and impairments make sense individually and collectively?
6. **What subjective accounting judgements and estimates has the company made? Do these make logical sense and are they consistent with the wider environment?**
7. **Have there been any significant changes in the accounting choices and judgements during the period?**
8. **What assumptions are the company using and are those consistent across the accounts, with peers and in the wider economic environment?**
9. **Have any specific risks been identified by the audit committee and/or the auditor in relation to these balances?**
10. **Considering the accounting for costs as a whole, are there indications of selective accounting which may be an indicator of wider financial reporting governance concerns?**

### Conclusion

The use of exceptional items has not reduced significantly. Although that is not surprising, what did spark our interest was the level of their use had not seemed to materially improve. Although this is potentially the tail end of the impact of COVID-19 disruptions that were still being felt in the year end numbers, we would have expected there to have been a marked reduction. Perhaps this will come in the next half year results. It remains to be seen.

Despite the disruptions, the volume and magnitude of adjustments still appears to be significant. Whilst frustrating to analyse (e.g. deciding which ones to add back in) we think that it does provide the more detailed focused investor to gain a potentially advantageous insight into the company’s financial posture and governance.

# Disclosure appendix

The following analyst(s), who is(are) primarily responsible for this document, certifies(y) that the opinion(s), views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Dylan Whitfield, FCA, Mark McDonald and Rahul Chopra

This document has been issued by the Research Department of HSBC.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at [www.hsbcnet.com/research](http://www.hsbcnet.com/research).

## Additional disclosures

- 1 This report is dated as at 13 May 2022.
- 2 All market data included in this report are dated as at close 11 May 2022, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.

# Disclaimer

This document has been issued by HSBC Bank plc, which has based this document on information obtained from sources it believes to be reliable but which it has not independently verified. Neither HSBC Bank plc nor any member of its group companies ("HSBC") make any guarantee, representation or warranty nor accept any responsibility or liability as to the accuracy or completeness of this document and is not responsible for errors of transmission of factual or analytical data, nor is HSBC liable for damages arising out of any person's reliance on this information. The information and opinions contained within the report are based upon publicly available information at the time of publication, represent the present judgment of HSBC and are subject to change without notice.

This document is not and should not be construed as an offer to sell or solicitation of an offer to purchase or subscribe for any investment or other investment products mentioned in it and/or to participate in any trading strategy. It does not constitute a prospectus or other offering document. Information in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on it, consider the appropriateness of the information, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.

The decision and responsibility on whether or not to purchase, subscribe or sell (as applicable) must be taken by the investor. In no event will any member of the HSBC group be liable to the recipient for any direct or indirect or any other damages of any kind arising from or in connection with reliance on any information and materials herein.

Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed. Some of the statements contained in this document may be considered forward looking statements which provide current expectations or forecasts of future events. Such forward looking statements are not guarantees of future performance or events and involve risks and uncertainties. Actual results may differ materially from those described in such forward-looking statements as a result of various factors.

This document is for information purposes only and may not be redistributed or passed on, directly or indirectly, to any other person, in whole or in part, for any purpose. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report, you agree to be bound by the foregoing instructions. If this report is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. The document is intended to be distributed in its entirety. Unless governing law permits otherwise, you must contact a HSBC Group member in your home jurisdiction if you wish to use HSBC Group services in effecting a transaction in any investment mentioned in this document.

Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document.

HSBC and/or its officers, directors and employees may have positions in any securities in companies mentioned in this document. HSBC may act as market maker or may have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell or buy securities and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented on the supervisory board or any other committee of those companies.

From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

HSBC Bank plc is registered in England No 14259, is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange. (070905)

© Copyright 2022, HSBC Bank plc, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of insert issuing entity name. MCI (P) 037/01/2022, MCI (P) 017/10/2021

[1192657]